跳至主要内容
临床试验/NCT02156050
NCT02156050Unknown4 期

Utilisation du Dispositif BBloo® Pour le Traitement de l'ictère néonatal : Satisfaction Des Parents et Des Personnels Soignants

Association Pédiatrique des Groupes d'Acuueil et de Recherche4 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2013年12月1日最近更新:
适应症

试验速览

阶段
4 期
发起方
入组人数
80
试验地点
4
主要终点
EDIN Scale

研究概览

简要总结

Jaundice occurs in most newborn infants. Most jaundice is benign, but because of the potential toxicity of bilirubin, newborn infants must be monitored to identify those who might develop severe hyperbilirubinemia an, in rare cases, acute bilirubin encephalopathy or kernicterus. Jaundice is a commonly observed, usually harmless condition in newborn infants during the first week after birth. However, in some babies the amount of bilirubin pigment can increase to dangerous levels and require treatment. Treatment of jaundice in newborn infants is done by placing them under phototherapy, a process of exposing their skin to light of a specific wavelength band. Fluorescent tubes or halogen lamps have been used as light sources for phototherapy for many years. A light-emitting diode (LED) is a newer type of light source which is power efficient, has a longer life and is portable with low heat production. Several technologies and devices are developed around this LED and specially a compact system.

The purpose of this study is to evaluate efficacity of LED phototherapy by comparing with conventional phototherapy (non-LED) and satisfaction of the parents and the professional staff about comfort of this new technology. The newborn infant is placed in a sleeper with the device B' bloo ® which maintains him in position (lap or dorsal) allowing to pass the blue light. This one is generated by the module LED and transmitted in the braid of optical fibers which takes place directly on the mattress of the cradle in which is placed the patient usually.

The device is endowed with an hour counter to schedule the time of treatment. The energy illumination varies between 3 and 4 mW / cm ² for an average 3,6 mW / cm ².

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
35 Weeks 至 42 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • Newborn infants ≥ 38 gestation weeks without or with risk factors of severe icterus (G6PD or pyruvate-kinase deficiency, red blood cells membrane defects, hemoglobinopathies, cephalohematoma or significant bruising, decreased breastfeeding)
  • newborn at 35 and 38 gestation weeks without risk factor of severe icterus (qs)
  • hyperbilirubinemia to deal according to the curves of indication of phototherapy of the APP on 2004
  • no opposition of parents

排除标准

  • opposition of parents
  • newborn infants less than 33 weeks
  • newborn infants at 35 or more weeks of gestation with risk factors of severe icterus
  • Jaundice in first 12 hours
  • Hyperbilirubinemia > 340 µmol/L whatever is the age

结局指标

主要结局

EDIN Scale

时间窗: base line, 60minutes, 240minutes

EDIN scale will be measured 3 times during phototherapy treatment (base line, at 1 hour and at 4 Hour)

次要结局

  • Evaluation of Blood Bilirubin level(base line, at 12 hour and at 24 hour)

研究者

发起方
Association Pédiatrique des Groupes d'Acuueil et de Recherche
申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验